Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 9/20 | 0.47 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL972969 | 1.00 | CYP1A1 (0.47) | CYP1A1CYP1B1MAOBNR4A1NR4A2 | |
| SCHEMBL12444114 | 0.82 | NR4A1 (0.39) | CYP1A1CYP1B1MAOBNR4A1NR4A2 | |
| SCHEMBL2271850 | 0.78 | NR4A1 (0.57) | CYP1A1CYP1B1MAOBNR4A1NR4A2 | |
| SCHEMBL2271846 | 0.78 | NR4A1 (0.57) | CYP1A1CYP1B1MAOBNR4A1NR4A2 | |
| SCHEMBL3391803 | 0.76 | ALDH1A1 (0.60) | MAOBNR4A1NR4A2NR4A3CES2 | |
| SCHEMBL970479 | 0.75 | CYP1A1 (0.46) | CYP1A1CYP1B1MAOBNR4A1NR4A2 | |
| SCHEMBL970477 | 0.75 | CYP1A1 (0.46) | CYP1A1CYP1B1MAOBNR4A1NR4A2 | |
| SCHEMBL25142208 | 0.75 | NR4A1 (0.54) | CYP1A1CYP1B1MAOBNR4A1NR4A2 | |
| SCHEMBL970954 | 0.75 | NR4A1 (0.50) | CYP1A1CYP1B1MAOBNR4A1NR4A2 | |
| SCHEMBL12921442 | 0.75 | NR4A1 (0.50) | CYP1A1CYP1B1MAOBNR4A1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703793-B2 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| EP-2268644-B1 | TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION | BOEHRINGER INGELHEIM INT (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110021550-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021550-A1 | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation | COQ8A, TNNT2, TBXA2R | CYP1A1 150/4885CYP1B1 489/4885MAOB 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.